One molecule, two effects: A new drug concept to treat obesity and type 2 diabetes

A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signaling pathway as a "door opener" and delivers an additional metabolic modulator specifically into the